TenNor Therapeutics (Suzhou) Limited released its monthly return for the period ended 31 August 2026, confirming that both authorised and issued share capital remained unchanged throughout the month.

The filing indicates: • Authorised/issued ordinary H shares stood at 52.33 million shares with a par value of RMB 1 each, representing total share capital of RMB 52.33 million. • No new shares were issued, repurchased or cancelled, and the company held no treasury shares. • The public float met the Main Board’s 25 percent minimum threshold, with management explicitly confirming compliance.

No share options, warrants, convertibles or other equity-linked instruments were outstanding or exercised during the month, underscoring a stable capital structure. The document was signed by Chairman and CEO Ma Zhenkun and submitted to Hong Kong Exchanges and Clearing Limited on 2 September 2026.